Huawei Hengyuan Company
%20.jpg)
Huawei Hengyuan is a biomedical technology company dedicated to the preparation of Sertoli cells (with immune immunity) in vitro using cell reprogramming technology, mainly for: autoimmune diseases (such as rheumatoid arthritis); reproductive adjuvant therapy; human body Chronic diseases (such as Parkinson's); organ/tissue colonization (such as skin allograft).
Founded Date:
2018-12-01
Last Funding Type:
Seed
Headquarters:
Beijing, Beijing, China
Investors Number:
1
Technology:
Regenerative Medicine
Employee Number:
11-50
Industry:
Biotechnology, Health Care, Science and Engineering
Last Funding Date:
2019-02-25
Funding Status:
Seed
Investor Type:
For Profit